18 June 2013
Keywords: phase, ii, trial, repligen, rpf4, started, study
Article | 06 December 1993
Repligen has started a Phase II study of its recombinant platelet factor
4 product for reversing heparin anticoagulation. The 40-patient,
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
6 December 1993
13 December 1993
© 2013 thepharmaletter.com